Presentation is loading. Please wait.

Presentation is loading. Please wait.

Key Variables in ICS Assays

Published byDavin Josselyn Modified over 10 years ago

Similar presentations

Presentation on theme: "Key Variables in ICS Assays"— Presentation transcript:

1 Key Variables in ICS Assays
Holden T. Maecker

2 The original BD ICS assay protocol
1 ml whole blood + Ag + CD28 + CD49d + Brefeldin A + FACSLyse, 10 min + EDTA/PBS 2h 4h 15 min Centrifuge, aliquot into staining tubes or freeze Wash Wash, fix, analyze CD69 PE anti-TNF FITC FACS Perm, 10 min mAb staining, 30-60 min 3- or 4-color Flow cytometry

3 96-well plate ICS protocol with lyophilized reagents
PBMC or whole blood Plate with lyophilized Ag+BFA 37oC, EDTA, FACS Lyse, FACS Perm 2 Plate with lyophilized Ab to flow cytometer

4 What are the key variables?
Stimulation PBMC vs. whole blood Resting PBMC before activation Activation/staining in plates vs. tubes Costimulatory Abs (CD28+CD49d) Stimulation time Brefeldin A and/or monensin Processing and staining Use of EDTA or not Method of fixation/permeabilization Freezing of cells post-fixation Surface vs. intracellular staining for CD3, CD4, CD8, etc. Fluorochromes and fixation (APC-Cy7, AmCyan) Staining time, temperature, and agitation Number of washes (post-fix and post-stain) Acquisition and analysis Number of events to collect Gating Interpretation of results, precision, comparisons with other assays

5 Effect of overnight rest on cryo PBMC
% IFNg+ MFI of IFNg+ 3 750 2 500 1 250 100 10000 100 10000 Reciprocal Dilution Reciprocal Dilution No rest, 6 h peptide stimulation Overnight rest, 6 h peptide stimulation

6 Correlation of tube vs. plate ICS
A. 96-well whole blood B. 96-well PBMC CD4 CD8 CD4 CD8 1.25 2.5 4 4 1.00 2.0 3 3 Peptide mix % IFNg+ cells 0.75 1.5 2 2 0.50 r 2 = 0.95 1.0 r 2 =0.87 r 2 = 0.96 r 2 = 0.73 p<0.0001 p<0.0001 p < p = 0.25 1 1 slope 0.94 0.5 slope 0.88 slope = 1.2 slope = 1.1 0.00 0.0 plate 0.00 0.25 0.50 0.75 1.00 1.25 0.0 0.5 1.0 1.5 2.0 2.5 1 2 3 4 1 2 3 4 0.0 2.5 5.0 7.5 10.0 2 4 6 8 10 12 14 10 20 10 20 30 % IFNg+ cells SEB 2 2 r = 0.94 r 2 =0.95 r = 0.74 r 2 = 0.79 p<0.0001 p = p < p<0.0001 slope = 0.84 slope 0.91 slope 0.93 slope = 0.78 % IFNg+ cells % IFNg+ cells % IFNg+ cells % IFNg+ cells tube

7 Similar IFNg MFI in tubes vs. plates
A. 96-well whole blood B. 96-well PBMC C. 24-well whole blood (HIV+) CD4 CD8 1 2 3 CD4 CD8 1 2 3 CD4 CD8 1 2 3 t u b e p l a t e IFNg mean fluorescence

8 Cell recovery in tubes vs. plates
1 7 5 % CD3+ cell recovery 5 2 5 Tube Tube 96-well 24-well 96-well Whole Blood PBMC

9 Effect of costimulatory Abs (CD28+49d)

10 Monensin vs. Brefeldin Summary
Brefeldin A preferred (10 mg/mL): TNFa, IFNg, IL-2, IL-4, IL-12 When combining any of the above with CD107, TGFb, or IL-10: 5 mg/mL monensin + 5 mg/mL brefeldin A

11 What are the key variables?
Stimulation PBMC vs. whole blood Resting PBMC before activation Activation/staining in plates vs. tubes Costimulatory Abs (CD28+CD49d) Stimulation time Brefeldin A and/or monensin Processing and staining Use of EDTA or not Method of fixation/permeabilization Freezing of cells post-fixation Surface vs. intracellular staining for CD3, CD4, CD8, etc. Fluorochromes and fixation (APC-Cy7, AmCyan) Staining time, temperature, and agitation Number of washes (post-fix and post-stain) Acquisition and analysis Number of events to collect Gating Interpretation of results, precision, comparisons with other assays

12 EDTA addition in plates and tubes

13 Fix/perm comparison: monocyte IL-12

14 Fix/perm comparison: T cell TGFb
BD FACS Lysing Solution BD Cytofix/Cytoperm BD FACS Permeabilizing Sol’n BD Perm Wash TGFb PE TGFb PE TGFb PE TGFb PE

15 TGFb staining and activation media
TGFb PE TGFb PE TGFb PE

16 Freezing activated cells in FACS Lyse

17 Surface vs. IC staining for CD3
SEB stimulated PBMCs surface stain intracellular stain CD3 Alexa 700 Clone

18 Surface vs. IC staining for CD4 & CD8
surface stain intracellular stain SEB stimulated PBMCs CD8 APC-hilyte CD4 60ng CD8 Qdot 605 @ 0.25ul CD4 AmCyan @ 60ng

19 All events CD3+ gate B CD8 APC-Cy7 Side Light Scatter C A
CD3 Pacific Blue CD4 AmCyan CD4- CD8+ gate CD4+ CD8- gate IFNg FITC IFNg FITC IL-2 PE IL-2 PE CD8+ IFNg+ CD8+ IFNg+ IL-2+ CD4+ IFNg+ CD4+ IFNg+ IL-2+ Side Light Scatter Side Light Scatter Side Light Scatter Side Light Scatter CD27 APC CD27 APC CD27 APC CD27 APC CD45RA PE-Cy7 CD45RA PE-Cy7 CD45RA PE-Cy7 CD45RA PE-Cy7 CD45RA PE-Cy7 CD45RA PE-Cy7 CD45RA PE-Cy7 CD45RA PE-Cy7 CD28 PerCP-Cy5.5 CD28 PerCP-Cy5.5 CD28 PerCP-Cy5.5 CD28 PerCP-Cy5.5 CD28 PerCP-Cy5.5 CD28 PerCP-Cy5.5 CD28 PerCP-Cy5.5 CD28 PerCP-Cy5.5

20 Degradation of APC-Cy7 on stained cells
In BDSF

21 BDSF and AmCyan don’t mix

22 IC staining time, volume, and mixing

23 What are the key variables?
Stimulation PBMC vs. whole blood Resting PBMC before activation Activation/staining in plates vs. tubes Costimulatory Abs (CD28+CD49d) Stimulation time Brefeldin A and/or monensin Processing and staining Use of EDTA or not Method of fixation/permeabilization Freezing of cells post-fixation Surface vs. intracellular staining for CD3, CD4, CD8, etc. Fluorochromes and fixation (APC-Cy7, AmCyan) Staining time, temperature, and agitation Number of washes (post-fix and post-stain) Acquisition and analysis Number of events to collect Gating Interpretation of results, precision, comparisons with other assays

24 Number of events to acquire
CALCULATING SAMPLE SIZE FOR RARE EVENT ANALYSIS Enter the estimated values in the grey fields: % bkgd= 0.1 p(av)= 0.0015 %pos= 0.2 delta= 0.001 For power of 90%, p<0.05, N= 25761 For power of 99%, p<0.005, 71592 For power of 80%, p<0.05, 18572 _______________________________________________________________ ________# events to collect__________ % bkgd lowest % positive 90% power, p<0.05 99% power, p<0.005 0.01 0.02 260,000 720,000 0.05 32,000 90,000 12,000 67,000 190,000 16,000 45,000 0.03 170,000 480,000 23,000 63,000 0.04 33,000 93,000 52,000 140,000 0.06 86,000 240,000 0.07 160,000 450,000 0.08 17,000 46,000 26,000 72,000

25 Importance of gating dim cells

26 Multi-site lyophilized control cell data
Individual (Manual) Analysis Cocltail 1 CD4 Cocktail 1 CD8 Cocktail 2 CD4 Cocktail 3 CD8 10 20 30 32% 29% % % % cytokine+ cells Central (Automated) Analysis 7% % % %

27 Gating Manual analysis Batch analysis with dynamic gates 0.55% 0.56%
200 400 600 800 1000 Forward Scatter R1 10 1 2 3 4 CD3 APC R2 200 400 600 800 1000 Forward Scatter R1 10 1 2 3 4 R3 R2 CD3 APC ungated ungated ungated gated on R1 Side Scatter Side Scatter Side Scatter Side Scatter 10 1 2 3 4 CD3 APC R3 10 1 2 3 4 CD3 APC R4 R5 gated on R1 gated on R1&R2 &R3 ungated gated on R1&R3 &R5 R4 0.55% R6 0.56% CD8 PerCP-Cy5.5 CD69 PE CD8 PerCP-Cy5.5 CD69 PE R7 10 10 1 10 2 10 3 10 4 10 10 1 10 2 10 3 10 4 IFNg FITC IFNg FITC

28 What are the key variables?
Stimulation PBMC vs. whole blood Resting PBMC before activation Activation/staining in plates vs. tubes Costimulatory Abs (CD28+CD49d) Stimulation time Brefeldin A and/or monensin Processing and staining Use of EDTA or not Method of fixation/permeabilization Freezing of cells post-fixation Surface vs. intracellular staining for CD3, CD4, CD8, etc. Fluorochromes and fixation (APC-Cy7, AmCyan) Staining time, temperature, and agitation Number of washes (post-fix and post-stain) Acquisition and analysis Number of events to collect Gating Interpretation of results, precision, comparisons with other assays

29 Holden’s rules for ICS (and life)
Validate your assay, but don’t validate that the earth is round take advantage of others’ data if it’s sound Know the inherent variability in your assay don’t talk about significant differences unless you run at least triplicate samples Avoid comparing apples and oranges any changes to the assay can produce variability, so keep protocols constant and run samples in parallel whenever possible

30 Acknowledgements Laurel Nomura Smita Ghanekar Brinda Emu Maria Jaimes
Margaret Inokuma Sonny Bhatia Joyce Ruitenberg Maria Suni Jack Dunne Skip Maino Brinda Emu Rebecca Hoh Steve Deeks Jeff Martin Mike McCune Doug Nixon

31

Download ppt "Key Variables in ICS Assays"

Similar presentations

Supplementary Figure S1Wang et. al. Supplementary Figure S1: (a) Purity of transferred Tconv. Tconv (CD4 + CD45RB hi CD25 ) were sorted from the spleen.

Supplementary Figure S1Wang et. al. Supplementary Figure S1: (a) Purity of transferred Tconv. Tconv (CD4 + CD45RB hi CD25 ) were sorted from the spleen.
Research Techniques Made Simple: Flow Cytometry Richard R

Research Techniques Made Simple: Flow Cytometry Richard R
Supplementary Table 1. Immunological Characteristics of Patients.

Supplementary Table 1. Immunological Characteristics of Patients.
Supplementary Figure 3 A

Supplementary Figure 3 A
Anti-E1Anti-E2 rE1E2p7 protein VEE/SIN-E1E2P7 VEE/SIN-E1E2 33-35 rE1E2P7 protein VEE/SIN-E1E2P7 VEE/SIN-E1E2 EndoH 35 25 15 75 50 35 25 r E1E2p7 protein)

Anti-E1Anti-E2 rE1E2p7 protein VEE/SIN-E1E2P7 VEE/SIN-E1E rE1E2P7 protein VEE/SIN-E1E2P7 VEE/SIN-E1E2 EndoH r E1E2p7 protein)
Introduction to Flow Cytometry

Introduction to Flow Cytometry
Laboratory: Unit 3: isolate bacteria (pages 43-52) Unit 4: extract DNA (pages 71-83) Next Day: examine plates & streak Lecture: DNA extraction from bacterial.

Laboratory: Unit 3: isolate bacteria (pages 43-52) Unit 4: extract DNA (pages 71-83) Next Day: examine plates & streak Lecture: DNA extraction from bacterial.
Flow Cytometry What is Flow Cytometry? Introduction to Flow Cytometry

Flow Cytometry What is Flow Cytometry? Introduction to Flow Cytometry
Method: - 293 GT cells - average count of 1:2 and 1:4 dilutions was used to prepare cell titration (20,000, 5,000, 1,000, and 200) - cells seeded in morning,

Method: GT cells - average count of 1:2 and 1:4 dilutions was used to prepare cell titration (20,000, 5,000, 1,000, and 200) - cells seeded in morning,
A. a). d). c). f). b).e). g). Figure S1. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were simple.

A. a). d). c). f). b).e). g). Figure S1. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were simple.
Design and optimization of multicolor panels Holden T. Maecker.

Design and optimization of multicolor panels Holden T. Maecker.
Steps to Success with Multicolor Flow Cytometry

Steps to Success with Multicolor Flow Cytometry
Early HIV cohort: Frozen PBMC samples from all 37 HIV-1 infected subjects; (77% of subjects within 6 months of seroconversion) (HIV negative or control.

Early HIV cohort: Frozen PBMC samples from all 37 HIV-1 infected subjects; (77% of subjects within 6 months of seroconversion) (HIV negative or control.
Group B3 (BCG replacement strategy) Define the immunogenicity endpoints to be used for the preclinical studies and the clinical trial Claude MERIC, Narges.

Group B3 (BCG replacement strategy) Define the immunogenicity endpoints to be used for the preclinical studies and the clinical trial Claude MERIC, Narges.
Center of Excellence in Cancer Research Principles of flow cytometry

Center of Excellence in Cancer Research Principles of flow cytometry
Assays of Immune Function. Some Definitions BrdU: bromodeoxyuridine (incorporated into DNA during cell division) CBA: cytometric bead array DC: dendritic.

Assays of Immune Function. Some Definitions BrdU: bromodeoxyuridine (incorporated into DNA during cell division) CBA: cytometric bead array DC: dendritic.
“Measuring Antigen Specific T- cells using Surface and Intracellular Staining Polychromatic Flow Cytometry” 3 rd Annual CFAR Flow Cytometry Workshop 6-10.

“Measuring Antigen Specific T- cells using Surface and Intracellular Staining Polychromatic Flow Cytometry” 3 rd Annual CFAR Flow Cytometry Workshop 6-10.
Basics of Flow Cytometry Holden Maecker. Outline Definitions, what can be measured by flow cytometry Fluidics: Sheath and sample streams, flow cells,

Basics of Flow Cytometry Holden Maecker. Outline Definitions, what can be measured by flow cytometry Fluidics: Sheath and sample streams, flow cells,
Intracellular Cytokine Staining (ICS) Flow Cytometry Assay 1 Kent J. Weinhold, Duke CFAR Director November 6th, 2013 CFAR Director’s Meeting Flow Cytometry.

Intracellular Cytokine Staining (ICS) Flow Cytometry Assay 1 Kent J. Weinhold, Duke CFAR Director November 6th, 2013 CFAR Director’s Meeting Flow Cytometry.
Group A3: Immunological endpoints Yacouba Cissoko Agustina Errea Mamadou Korka Diallo.

Group A3: Immunological endpoints Yacouba Cissoko Agustina Errea Mamadou Korka Diallo.

Similar presentations

Ads by Google